Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.

In early August 2026, Exelixis reported second-quarter results showing revenue of US$628.69 million and net income of US$212.05 million, with earnings per share increasing versus the prior year, but slightly trailing revenue expectations. Alongside lowering its 2026 revenue outlook to US$2.50 billion–US$2.55 billion, the company highlighted slower growth in the neuroendocrine tumor indication and continued investment in its zanzalintinib pipeline and share repurchase activities. We’ll now...

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Exelixis Inc (EXEL) reports robust Q2 2026 results with $629M in revenues, while navigating slower NET adoption and advancing its zanzalintinib pipeline toward key regulatory milestones.

Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Exelixis stock toppled late Wednesday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.

Expand Energy (NASDAQ:EXE) said its second-quarter operating performance and capital allocation actions reinforced its strategy of becoming an integrated natural gas company, highlighting debt reduction, share repurchases, organic lease additions and its planned acquisition of natural gas marketer T

They are riding strong tailwinds that could lift them higher.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.